194 related articles for article (PubMed ID: 35129210)
21. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
Neumann PJ; Crummer E; Chambers JD; Tunis SR
Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
[TBL] [Abstract][Full Text] [Related]
22. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
Yuksel JM; Noviasky J; Britton S
Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
[No Abstract] [Full Text] [Related]
23. Aducanumab-Hope or Disappointment for Alzheimer's Disease.
Wojtunik-Kulesza K; Rudkowska M; Orzeł-Sajdłowska A
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901797
[TBL] [Abstract][Full Text] [Related]
24. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
Vaz M; Silva V; Monteiro C; Silvestre S
Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
[TBL] [Abstract][Full Text] [Related]
25. Ignoring the Experts: Implications of the FDA's Aduhelm Approval.
Maulden A
Am J Law Med; 2022 Mar; 48(1):108-133. PubMed ID: 35815585
[TBL] [Abstract][Full Text] [Related]
26. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
Mukhopadhyay S; Banerjee D
J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
[TBL] [Abstract][Full Text] [Related]
27. Can we learn lessons from the FDA's approval of aducanumab?
Liu KY; Howard R
Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
[TBL] [Abstract][Full Text] [Related]
28. Of education and public policy: Aducanumab.
Lundebjerg NE; Hollmann PA; Supiano MA
J Am Geriatr Soc; 2022 Jan; 70(1):81-84. PubMed ID: 34674219
[No Abstract] [Full Text] [Related]
29. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.
Lythgoe MP; Prasad V
Eur J Cancer; 2021 Nov; 157():68-70. PubMed ID: 34487987
[No Abstract] [Full Text] [Related]
30. [Aducanumab approval for Alzheimer's disease in the USA: the surrender of science].
Dal-Ré R
Rev Neurol; 2021 Oct; 73(8):296-297. PubMed ID: 34617583
[TBL] [Abstract][Full Text] [Related]
31. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
Rabinovici GD
N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
[No Abstract] [Full Text] [Related]
32. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.
Knopman DS; Jones DT; Greicius MD
Alzheimers Dement; 2021 Apr; 17(4):696-701. PubMed ID: 33135381
[TBL] [Abstract][Full Text] [Related]
33. Aducanumab for Alzheimer's disease: A regulatory perspective.
Nisticò R; Borg JJ
Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
[TBL] [Abstract][Full Text] [Related]
34. Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
Anderson TS; Ayanian JZ; Souza J; Landon BE
JAMA; 2021 Oct; 326(16):1627-1629. PubMed ID: 34499725
[TBL] [Abstract][Full Text] [Related]
35. Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab.
Chin E; Jaqua E; Safaeipour M; Ladue T
Cureus; 2022 Nov; 14(11):e31065. PubMed ID: 36475205
[TBL] [Abstract][Full Text] [Related]
36. Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review.
Beshir SA; Aadithsoorya AM; Parveen A; Goh SSL; Hussain N; Menon VB
Int J Alzheimers Dis; 2022; 2022():9343514. PubMed ID: 35308835
[TBL] [Abstract][Full Text] [Related]
37. Aducanumab: The first targeted Alzheimer's therapy.
Yang P; Sun F
Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
[TBL] [Abstract][Full Text] [Related]
38. Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform.
Herder M
J Law Med Ethics; 2023; 51(4):900-919. PubMed ID: 38477277
[TBL] [Abstract][Full Text] [Related]
39. A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer's Disease.
Yeo-Teh NSL; Tang BL
Sci Eng Ethics; 2023 Jan; 29(1):2. PubMed ID: 36625928
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the First Round of Public Comments for the National Coverage Determination for Monoclonal Antibodies in the Treatment of Alzheimer's Disease.
Wahl J; Gadbois EA
J Aging Soc Policy; 2023 Jul; ():1-20. PubMed ID: 37486161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
